Radar › Screener › ESLA

ESLA

Estrella Immunopharma, Inc.
ESLA stock: delisting risk — what the SEC filings say, updated every weekday morning.
Nasdaq · Biological Products, (No Diagnostic Substances) · EDGAR filings (CIK 1844417) · 6 signals · 1 setups · updated Sep 22, 2026

What the filings say Pressure ▼

Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.

Radar 87 (high attention) · dilution pressure elevated · listing risk high · governance risk low · runway 0.1 mo · strongest signal: Hearings panel (Sep 8, 2026)

What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

Get tomorrow's read on ESLA — free
One email every weekday morning: what changed across ESLA and ~1,400 other microcaps, every claim linked to the filing.
87Radar · attention score (0–100)
65Dilution pressure · financing + balance sheet
83Listing risk · exchange standards
0Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Listing cliff Pressure ▼ strength 0.90

Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.

Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Delisting languageHearings panelExchange deficiency noticeNegative equityRunway < 6 months

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on ESLA
Alerts
One email the morning ESLA files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for ESLA back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 892 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$100Kcash + short-term investments as of Jun 30, 2026
0.1 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$-7.4Mstockholders' equity as of Jun 30, 2026
$20.5Mpublic float (10-K cover)
43.5Mshares outstanding as of Aug 11, 2026 · was 43.0M May 11, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Sep 8, 2026▼ Hearings panel “hearings panel” language in 8-K (8-K) filed 2026-09-08 filing 58
Sep 8, 2026▼ Exchange deficiency notice 8-K Item 3.01 filed 2026-09-08 (accepted 17:25 ET) filing 51
Sep 8, 2026▼ Delisting language “delisting notice” language in 8-K (8-K) filed 2026-09-08 filing 47
Jun 30, 2026▼ Runway < 6 months ~0.1 months runway: liquidity $100,000 as of 2026-06-30, burn $17,193,017/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 46
Jun 30, 2026▼ Negative equity Stockholders' equity $-7,431,333 as of 2026-06-30 filing 31
Jun 30, 2026▼ Cash < current liabilities Liquidity $100,000 vs current liabilities $9,256,014 filing 22

Other listing cliff setups

DAIC CID Holdco, Inc. · SDST Stardust Power Inc. · ISPC iSpecimen Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · BRTX BioRestorative Therapies, In · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans